• Ascendis Pharma plans its first EU launch of TransCon CNP as YUVIWEL in Germany in Q1 2027, subject to European Commission authorization.
• A final authorization decision is expected in Q4 2026 for treating achondroplasia in children aged two and older with open epiphyses.
• EMA's orphan medicines committee recommended maintaining orphan designation, potentially providing 10 years of EU market exclusivity upon European Commission adoption.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611060800OMX_____CNEWS_EN_GNW9872125_en) on November 06, 2026, and is solely responsible for the information contained therein.